摘要:
The invention relates to a method of inactivating lipid-enveloped viruses by means of a non-ionic detergent, and the preparation of a vaccine containing the inactivated virus. The invention further relates to an inactivated virus which is characterized by its structural integrity, in particular the structural integrity of its enveloping proteins, as well as to the use of the inactivated virus for preparing a vaccine.
摘要:
There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.
摘要:
There is disclosed a purified multimerase having an indirect and a direct proteolytic activity, which converts vWF having a singlet structure to vWF having a satellite structure and is active in the presence of the serine protease inhibitor DFP or the calpain protease inhibitor Z-Leu-Leu-Tyr-CHN.sub.2, as well as a method of preparing the multimerase according to the invention.
摘要:
The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
摘要:
Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
摘要:
Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion.
摘要:
A native, chromatographically purified α1-AT preparation having a purity of at least 0.7 PU/mg protein and a relative plasma α1-AT activity of at least 120% is disclosed. The ratio of active to inactive α1-AT is higher than in plasma.Furthermore, a method of producing this preparation is disclosed, as well as the use of a carrier material, e.g. an inorganic carrier material such as hydroxylapatite for separating active α1-AT from inactive α1-AT.
摘要:
There is disclosed a method of recovering factor VIII/vWF-complex which is characterized in that factor VIII/vWF-complex from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of factor VIII/vWF-complex , which particularly contains high-molecular vWF multimers, as well as a factor VIII/vWF-complex obtainable by means of cation exchange chromatography.